| Karimpumanil Mathai Kurien, MD | |
|
1200 Old York Rd, Abington, PA 19001-3720 | |
| (215) 481-2000 | |
| Not Available |
| Full Name | Karimpumanil Mathai Kurien |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 41 Years |
| Location | 1200 Old York Rd, Abington, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841292034 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD061977L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abington Memorial Hospital | Abington, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| United Anesthesia Services Pc | 3173437613 | 371 |
News Archive
Patient Safety Technologies, Inc. today announced the closing of a $7.1 million common stock financing. The investors, led by a new institutional investor, together with several existing shareholders and certain members of senior management, purchased 9.48 million shares of common stock at a price of $0.75 per share.
Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either REVLIMID (lenalidomide), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of REVLIMID plus low-dose dexamethasone (Rd) were presented during the 51st American Society of Hematology's annual meeting in New Orleans, LA.
The microbes could surrender to the harmless virus, but instead freeze in place, dormant, waiting for their potential predator to go away, according to a recent study in mBio.
Their work on targeting individual genes for more effective and cheaper drug testing opens the way to treatments for a huge range of diseases including diabetes and atherosclerosis, which leads to strokes and heart attacks.
› Verified 4 days ago
| Entity Name | United Anesthesia Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053366062 PECOS PAC ID: 3173437613 Enrollment ID: O20031118000620 |
News Archive
Patient Safety Technologies, Inc. today announced the closing of a $7.1 million common stock financing. The investors, led by a new institutional investor, together with several existing shareholders and certain members of senior management, purchased 9.48 million shares of common stock at a price of $0.75 per share.
Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either REVLIMID (lenalidomide), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of REVLIMID plus low-dose dexamethasone (Rd) were presented during the 51st American Society of Hematology's annual meeting in New Orleans, LA.
The microbes could surrender to the harmless virus, but instead freeze in place, dormant, waiting for their potential predator to go away, according to a recent study in mBio.
Their work on targeting individual genes for more effective and cheaper drug testing opens the way to treatments for a huge range of diseases including diabetes and atherosclerosis, which leads to strokes and heart attacks.
› Verified 4 days ago
| Entity Name | Childrens Anesthesiology Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689779480 PECOS PAC ID: 5799688529 Enrollment ID: O20040324000032 |
News Archive
Patient Safety Technologies, Inc. today announced the closing of a $7.1 million common stock financing. The investors, led by a new institutional investor, together with several existing shareholders and certain members of senior management, purchased 9.48 million shares of common stock at a price of $0.75 per share.
Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either REVLIMID (lenalidomide), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of REVLIMID plus low-dose dexamethasone (Rd) were presented during the 51st American Society of Hematology's annual meeting in New Orleans, LA.
The microbes could surrender to the harmless virus, but instead freeze in place, dormant, waiting for their potential predator to go away, according to a recent study in mBio.
Their work on targeting individual genes for more effective and cheaper drug testing opens the way to treatments for a huge range of diseases including diabetes and atherosclerosis, which leads to strokes and heart attacks.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karimpumanil Mathai Kurien, MD 610 W Germantown Pike Ste 150, Plymouth Meeting, PA 19462-1062 Ph: () - | Karimpumanil Mathai Kurien, MD 1200 Old York Rd, Abington, PA 19001-3720 Ph: (215) 481-2000 |
News Archive
Patient Safety Technologies, Inc. today announced the closing of a $7.1 million common stock financing. The investors, led by a new institutional investor, together with several existing shareholders and certain members of senior management, purchased 9.48 million shares of common stock at a price of $0.75 per share.
Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either REVLIMID (lenalidomide), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of REVLIMID plus low-dose dexamethasone (Rd) were presented during the 51st American Society of Hematology's annual meeting in New Orleans, LA.
The microbes could surrender to the harmless virus, but instead freeze in place, dormant, waiting for their potential predator to go away, according to a recent study in mBio.
Their work on targeting individual genes for more effective and cheaper drug testing opens the way to treatments for a huge range of diseases including diabetes and atherosclerosis, which leads to strokes and heart attacks.
› Verified 4 days ago
Denise Mann, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 | |
Patrick B Breen, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 | |
Daniel Maloney, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 | |
Dr. Patrick P Shum, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-8681 | |
Robert Louis Koniuta, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 | |
Joshua Burdick-will, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-480-2000 | |
Dr. Naheed G Mohammed, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 |